Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel

J Invasive Cardiol. 2008 May;20(5):E146-9.

Abstract

Acute myocardial infarction (AMI) during pregnancy, though rare, is nevertheless associated with a high mortality rate ranging from 37-50%. Percutaneous coronary intervention (PCI) with stenting is considered to be one of the more challenging therapeutic strategies in the management of AMI during pregnancy. We report a case of a 44-year-old pregnant woman who presented with an AMI. She underwent PCI using a drug-eluting stent (DES) with eptifibatide, aspirin and clopidogrel without complications, and later delivered a healthy infant at 36 weeks of gestation. With a tendency towards an increased proportion of births by older women, AMI during pregnancy may become more frequent. The risks and benefits of DES placement and the use of adjuvant antiplatelet therapy for coronary interventions during pregnancy are discussed here.

Publication types

  • Case Reports

MeSH terms

  • Aspirin / administration & dosage*
  • Clopidogrel
  • Coronary Angiography
  • Drug-Eluting Stents*
  • Electrocardiography
  • Female
  • Humans
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / surgery
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / diagnostic imaging
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Complications, Cardiovascular / surgery
  • Prosthesis Implantation
  • Ticlopidine / administration & dosage
  • Ticlopidine / analogs & derivatives*
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Clopidogrel
  • Ticlopidine
  • Aspirin